

Adriamycin (doxorubicin)

Effective Date: 10/22/13

Date Developed: 9/3/13 by Albert Reeves MD

Last Approval Date 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20

Adriamycin inhibits nucleotide replication and the action of DNA and RNA polymerases via nucleotide base intercalation (a form of substitution).

Prior Authorization Criteria:

Treatment of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) Hodgkin's Disease, malignant lymphoma, soft tissue and bone sarcomas, thyroid cancer, small cell lung cancer, breast cancer, gastric cancer, ovarian cancer, bladder cancer, neuroblastoma, and Wilm's tumor, as a component of multi-agent adjuvant chemotherapy for axillary node involvement following resection of primary breast cancer.

Unlabeled:

Treatment of multiple myeloma, endometrial carcinoma, uterine sarcoma, head and neck cancer, liver cancer, kidney cancer, Waldenstrom macroglobulinemia.

Note: **See VCHCP Policy for Prescription Medication for Off-Label Use for details.**

Dosage: Usual or typical adult dosages: I.V.: 60-75 mg/m²/dose every 21 days

Usual/typical pediatric dosages: I.V.: 35-75 mg/m²/dose every 21 days

Note: Refer to product literature for specific dosing protocols for each disease and for hepatic impairment

Note: Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing

Dosing: Adjustment for Toxicity

The following delays and/or dose reductions have been used:

Neutropenic fever/infection: Consider reducing to 75% of dose in subsequent cycles ANC

<1000/mm³: Delay treatment until ANC recovers to ≥1000/mm³

Platelets <100,000/mm³: Delay treatment until platelets recover to ≥100,000/mm³

How Supplied: 2mg/mL (5, 10, 25, 100 mL)

Precautions: acute and chronic cardiotoxicity (dysrhythmias, CHF); neutropenia; thrombocytopenia; alopecia; secondary malignancy (AML,MDS); miscellaneous (from case reports; see product literature)

References:

1. Berg SL, Grisell DL, DeLaney TF, et al, "Principles of Treatment of Pediatric Solid Tumors," *Pediatr Clin North Am*, 1991, 38(2):249-67. [PubMed 2006077]
2. Brown JR and Iman SH, "Recent Studies on Doxorubicin and Its Analogues," *Prog Med Chem*, 1984, 21:169-236. [PubMed 6400135]
3. Cummings J and Smyth JF, "Pharmacology of Adriamycin: The Message to the Clinician," *Eur J Cancer Clin Oncol*, 1988, 24(4):579-82. [PubMed 3289943]
4. Curran CF, "Acute Doxorubicin Overdoses," *Ann Intern Med*, 1991, 115(11):913-4.
5. Curran CF and Luce JK, "Accidental Acute Exposure to Doxorubicin," *Cancer Nurs*, 1989, 12(6):329- 31. [PubMed 2590899]
6. Davis HL and Davis TE, "Daunorubicin and Adriamycin in Cancer Treatment: An Analysis of Their Roles and Limitations," *Cancer Treat Rep*, 1979, 63(5):809-15. [PubMed 378369]
7. Floyd J, Mirza I, Sachs B, et al, "Hepatotoxicity of Chemotherapy," *Semin Oncol*, 2006, 33(1):50-67. [PubMed 16473644]
8. Floyd JD, Nguyen DT, Lobins RL, et al, "Cardiotoxicity of Cancer Therapy," *J Clin Oncol*, 2005, 23(30):7685-96. [PubMed 16234530]
9. Gordon KB, Tajuddin A, Guitart J, et al, "Hand-Foot Syndrome Associated With Liposome-Encapsulated Doxorubicin Therapy," *Cancer*, 1995, 75(8):2169-73. [PubMed 7697608]
10. Griggs JJ, Mangu PB, Anderson H, et al, "Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline," *J Clin Oncol*, 2012, 30(13):1553-61. [PubMed 22473167]
11. Ishii E, Hara T, Ohkubo K, et al, "Treatment of Childhood Acute Lymphoblastic Leukemia With Intermediate Dose Cytosine Arabinoside and Adriamycin," *Med Pediatr Oncol*, 1986, 14(2):73-7. [PubMed 3458999]
12. King PD and Perry MC, "Hepatotoxicity of Chemotherapy," *Oncologist*, 2001, 6(2):162-76. [PubMed 11306728]
13. Lauvin R, Miglianico L, and Hellegouarc'h R, "Skin Cancer Occurring 10 Years After the Extravasation of Doxorubicin," *N Engl J Med*, 1995, 332(11):754.
14. Legha SS, Benjamin RS, Mackay B, et al, "Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion," *Ann Intern Med*, 1982, 96(2):133-9. [PubMed 7059060]
15. Morgan C, Tillett T, Braybrooke J, et al, "Management of Uncommon Chemotherapy-Induced Emergencies," *Lancet Oncol*, 2011, 12(8):806-14. [PubMed 21276754]
16. Namer M, "Anthracyclines in the Adjuvant Treatment of Breast Cancer," *Drugs*, 1993, 45(Suppl 2):4-9. [PubMed 7693421]
17. National Comprehensive Cancer Network® (NCCN), "Clinical Practice Guidelines in Oncology™: Breast Cancer," Version 2.2011. Available at http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
18. National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at <http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf>. Accessed January 21, 2013.
19. Seifert CF, Nesser ME, and Thompson DF, "Dexrazoxane in the Prevention of Doxorubicin-Induced Cardiotoxicity," *Ann Pharmacother*, 1994, 28(9):1063-72. [PubMed 7803884]
20. Speth PA, van Hoesel QG, and Haanen C, "Clinical Pharmacokinetics of Doxorubicin," *Clin Pharmacokinet*, 1988, 15(1):15-31. [PubMed 3042244]
21. Speyer JL, Green MD, Kramer E, et al, "Protective Effect of the Bispiperazinedione ICRF-187 Against

Doxorubicin-Induced Cardiac Toxicity in Women With Advanced Breast Cancer,” *N Engl J Med*, 1988, 319(12):745-52. [PubMed 3137469]

Revision History:

Date Approved by P&T Committee: 10/22/13
 Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
 Date Approved by P&T Committee: 1/28/14
 Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
 Date Approved by P&T Committee: 1/27/15
 Date Reviewed/Updated: 6/29/15 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/26/16
 Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/24/17
 Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/23/18
 Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/22/19
 Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 2/18/20

| Revision Date | Content Revised (Yes/No) | Contributors | Review/Revision Notes |
|---------------|--------------------------|--------------------------------------------|-----------------------|
| 1/24/17 | No | Catherine Sanders, MD; Robert Sterling, MD | Annual review |
| 1/23/18 | No | Catherine Sanders, MD; Robert Sterling, MD | Annual review |
| 1/22/19 | No | Catherine Sanders, MD; Robert Sterling, MD | Annual review |
| 2/18/20 | No | Howard Taekman, MD; Robert Sterling, MD | Annual review |